Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 196 JPY 0.51% Market Closed
Market Cap: 17.7B JPY
Have any thoughts about
Healios KK?
Write Note

Intrinsic Value

Healios KK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Healios KK stock under the Base Case scenario is 142.89 JPY. Compared to the current market price of 196 JPY, Healios KK is Overvalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
142.89 JPY
Overvaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Healios KK

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Healios KK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Healios KK?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Healios KK

Provide an overview of the primary business activities
of Healios KK.

What unique competitive advantages
does Healios KK hold over its rivals?

What risks and challenges
does Healios KK face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Healios KK.

Provide P/S
for Healios KK.

Provide P/E
for Healios KK.

Provide P/OCF
for Healios KK.

Provide P/FCFE
for Healios KK.

Provide P/B
for Healios KK.

Provide EV/S
for Healios KK.

Provide EV/GP
for Healios KK.

Provide EV/EBITDA
for Healios KK.

Provide EV/EBIT
for Healios KK.

Provide EV/OCF
for Healios KK.

Provide EV/FCFF
for Healios KK.

Provide EV/IC
for Healios KK.

Show me price targets
for Healios KK made by professional analysts.

What are the Revenue projections
for Healios KK?

How accurate were the past Revenue estimates
for Healios KK?

What are the Net Income projections
for Healios KK?

How accurate were the past Net Income estimates
for Healios KK?

What are the EPS projections
for Healios KK?

How accurate were the past EPS estimates
for Healios KK?

What are the EBIT projections
for Healios KK?

How accurate were the past EBIT estimates
for Healios KK?

Compare the revenue forecasts
for Healios KK with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Healios KK and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Healios KK against its competitors.

Analyze the profit margins
(gross, operating, and net) of Healios KK compared to its peers.

Compare the P/E ratios
of Healios KK against its peers.

Discuss the investment returns and shareholder value creation
comparing Healios KK with its peers.

Analyze the financial leverage
of Healios KK compared to its main competitors.

Show all profitability ratios
for Healios KK.

Provide ROE
for Healios KK.

Provide ROA
for Healios KK.

Provide ROIC
for Healios KK.

Provide ROCE
for Healios KK.

Provide Gross Margin
for Healios KK.

Provide Operating Margin
for Healios KK.

Provide Net Margin
for Healios KK.

Provide FCF Margin
for Healios KK.

Show all solvency ratios
for Healios KK.

Provide D/E Ratio
for Healios KK.

Provide D/A Ratio
for Healios KK.

Provide Interest Coverage Ratio
for Healios KK.

Provide Altman Z-Score Ratio
for Healios KK.

Provide Quick Ratio
for Healios KK.

Provide Current Ratio
for Healios KK.

Provide Cash Ratio
for Healios KK.

What is the historical Revenue growth
over the last 5 years for Healios KK?

What is the historical Net Income growth
over the last 5 years for Healios KK?

What is the current Free Cash Flow
of Healios KK?

Discuss the annual earnings per share (EPS)
trend over the past five years for Healios KK.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Healios KK

Current Assets 5.1B
Cash & Short-Term Investments 4.5B
Receivables 123m
Other Current Assets 421m
Non-Current Assets 7.7B
Long-Term Investments 2.8B
PP&E 474m
Intangibles 4.4B
Other Non-Current Assets 1m
Current Liabilities 4B
Accounts Payable 187m
Other Current Liabilities 3.8B
Non-Current Liabilities 7.1B
Long-Term Debt 5.2B
Other Non-Current Liabilities 1.8B
Efficiency

Earnings Waterfall
Healios KK

Revenue
549m JPY
Cost of Revenue
-108m JPY
Gross Profit
441m JPY
Operating Expenses
-3.5B JPY
Operating Income
-3.1B JPY
Other Expenses
-3.2B JPY
Net Income
-6.2B JPY

Free Cash Flow Analysis
Healios KK

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Healios KK's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
32/100
Profitability
Score

Healios KK's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Healios KK's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Short-Term Solvency
Long-Term Solvency
High D/E
26/100
Solvency
Score

Healios KK's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Healios KK

Wall Street analysts forecast Healios KK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Healios KK is 374 JPY with a low forecast of 323.2 JPY and a high forecast of 420 JPY.

Lowest
Price Target
323.2 JPY
65% Upside
Average
Price Target
374 JPY
91% Upside
Highest
Price Target
420 JPY
114% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Healios KK?

Click here to dive deeper.

Dividends

Healios KK
does not pay dividends
Shareholder Yield

Current shareholder yield for Healios KK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Healios KK Logo
Healios KK

Country

Japan

Industry

Biotechnology

Market Cap

17.7B JPY

Dividend Yield

0%

Description

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Contact

TOKYO-TO
Chiyoda-ku
19F, Yurakucho Denki Bldg. North Tower, 1-7-1, Yuraku-cho
www.healios.co.jp

IPO

2015-06-16

Employees

116

Officers

Chairman & CEO
Dr. Tadahisa S. Kagimoto M.D.
CFO, Executive Officer & Internal Director
Mr. Richard P. Kincaid
Executive VP, Chief Medical Officer and In Charge of Development & Human Resources & General Affairs
Mr. Masanori Sawada M.D., MBA, Ph.D.
Exec. Off., Chief Scientific Off., In Charge of Res. & Manufacturing and Head of Kobe Res. Institute
Mr. Kouichi Tamura Ph.D.
Managing Director
Mr. Yoshinari Matsuda

See Also

Discover More
What is the Intrinsic Value of one Healios KK stock?

The intrinsic value of one Healios KK stock under the Base Case scenario is 142.89 JPY.

Is Healios KK stock undervalued or overvalued?

Compared to the current market price of 196 JPY, Healios KK is Overvalued by 27%.

Back to Top